Amlodipine And Atorvastatin Tablet, Coated
NDC Package 66993-271-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Amlodipine And Atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate.Amlodipine. This formulation utilizes a tablet, coated delivery system. Marketed by Prasco Laboratories, this product is identified by NDC 66993-271 and is authorized under FDA application NDA021540.

Identification & Billing

NDC Package Code
66993-271-30
Package Description
30 TABLET, COATED in 1 BOTTLE
Product Code
11-Digit Billing Format
66993027130
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA
RxNorm Crosswalk
  • RxCUI: 404011 - amLODIPine besylate 5 MG / atorvastatin calcium 80 MG Oral Tablet
  • RxCUI: 404011 - amlodipine 5 MG / atorvastatin 80 MG Oral Tablet
  • RxCUI: 404011 - amlodipine (as amlodipine besylate) 5 MG / atorvastatin (as atorvastatin calcium) 80 MG Oral Tablet
  • RxCUI: 404013 - amLODIPine besylate 10 MG / atorvastatin calcium 80 MG Oral Tablet
  • RxCUI: 404013 - amlodipine 10 MG / atorvastatin 80 MG Oral Tablet

Clinical Specifications

Proprietary Name
Amlodipine And Atorvastatin
Non-Proprietary Name
Amlodipine And Atorvastatin
Substance Name
Amlodipine Besylate; Atorvastatin Calcium Trihydrate
Dosage Form
Tablet, Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is covered with a designated coating.
Administration Route
Oral - Administration to or by way of the mouth.
Usage Information
Amlodipine and atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate.Amlodipine

Regulatory & Marketing

Labeler Name
Prasco Laboratories
Product Type
Human Prescription Drug
FDA Application #
NDA021540
Marketing Category
NDA AUTHORIZED GENERIC - A product marketed as a "generic" drug under an approved New Drug Application (NDA), rather than an Abbreviated New Drug Application (ANDA),.
Start Marketing Date
03-14-2022
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 66993-271-30 identifies a specific commercial package of 30 tablet, coated in 1 bottle of Amlodipine And Atorvastatin, a human prescription drug labeled by Prasco Laboratories. This tablet, coated is formulated for oral use and contains amlodipine besylate; atorvastatin calcium trihydrate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Prasco Laboratories on March 14, 2022. The current certification is valid through December 31, 2027.

How is this Prasco Laboratories product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 66993027130. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
66993-271-30
11-Digit CMS (5-4-2)
66993-0271-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.